How key decisions slowed FDA’s review of Covid-19 vaccine — but also gave it important data
In September, as Pfizer and partner BioNTech were quickly advancing a study of their Covid-19 vaccine, dozens of well-known academics sent an open letter to Pfizer’s CEO with a simple plea: Please slow down and collect more data.
It was not until Nov. 20 that the data were submitted to the Food and Drug Administration.
